Statins and bone metabolism

Oral Diseases

Volumn 12, Issue 2, 2006, Pages 85-101

  Horiuchi, N ^a   Maeda, T ^a  

^a OHU UNIVERSITY   (Japan)

Author keywords

Bone formation; Osteoporosis; Periodontal disease; Pleiotropic effect; Statins; Vascular endothelial growth factor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANABOLIC AGENT; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; CALCITONIN; CERIVASTATIN; COMPACTIN; ESTRADIOL; ESTROGEN; FLUINDOSTATIN; FLUORIDE; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVALONIC ACID; MEVINOLIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PITAVASTATIN; PRAVASTATIN; RHO KINASE INHIBITOR; ROSIGLITAZONE; ROSUVASTATIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIMVASTATIN; STRONTIUM; UNINDEXED DRUG; VASCULOTROPIN; VITAMIN D DERIVATIVE;

ALVEOLAR BONE; ARTICLE; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE MINERALIZATION; BONE STRUCTURE; BONE TISSUE; BONE TURNOVER; CANCELLOUS BONE; CARDIOVASCULAR RISK; CELL ACTIVITY; CELL CULTURE; CELL DIFFERENTIATION; CHOLESTEROL SYNTHESIS; DEMENTIA; FRACTURE; HIP; HUMAN; ISCHEMIC HEART DISEASE; MANDIBLE; MOLAR TOOTH; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; OVARIECTOMY; PERIODONTAL DISEASE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK REDUCTION; SPINE; TOOTH EXTRACTION;

ALVEOLAR PROCESS; ANIMALS; ANTICHOLESTEREMIC AGENTS; BONE AND BONES; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; FRACTURES, BONE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OSTEOBLASTS; OSTEOPOROSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 33645160437     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2005.01172.x     Document Type: Article

References (150)

1. Aikawa M Rabkin E Voglic SJ et al 1998 Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma Circ Res 83 1015 1026
2. Ayukawa Y Okamura A Koyano K 2004 Simvastatin promotes osteogenesis around titanium implants Clin Oral Implants Res 15 346 350
3. Bauer DC 2003 HMG CoA reductase inhibitors and the skeleton: a comprehensive review Osteoporos Int 14 273 282
4. van Beek E Lowik C van der Pluijm G Papapoulos S 1999 The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates J Bone Miner Res 14 722 729
5. Bellosta S Via D Canavesi M et al 1998 HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages Arterioscler Thromb Vasc Biol 18 1671 1678
6. Bianco P Riminucci M Gronthos S Robey PG 2001 Bone marrow stromal stem cells: nature, biology, and potential applications Stem Cells 19 180 192
7. Black AE Hayes RN Roth BD Woo P Woolf TF 1999 Metabolism and excretion of atorvastatin in rats and dogs Drug Metab Dispos 27 916 923
8. Bonetti PO Lerman LO Napoli C Lerman A 2003 Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 24 225 248
9. Boutahar N Guignandon A Vico L Lafage-Proust MH 2004 Mechanical strain on osteoblasts activates autophosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 tyrosine sites involved in ERK activation J Biol Chem 279 30588 30599
10. Burkhardt R Kettner G Bohm W et al 1987 Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study Bone 8 157 164
11. Burnett JR Vasikaran SD 2002 Cardiovascular disease and osteoporosis: is there a link between lipids and bone Ann Clin Biochem 39 203 210
12. Casey PJ Seabra MC 1996 Protein prenyltransferases J Biol Chem 271 5289 5292
13. Chan KA Andrade SE Boles M et al 2000 Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women Lancet 355 2185 2188
14. Chan MH Mak TW Chiu RW Chow CC Chan IH Lam CW 2001 Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia J Clin Endocrinol Metab 86 4556 4559
15. Christiansen C Lindsay R 1990 Estrogens, bone loss and preservation Osteoporos Int 1 7 13
16. Corsini A Bellosta S Baetta R Fumagalli R Paoletti R Bernini F 1999 New insights into the pharmacodynamic and pharmacokinetic properties of statins Pharmacol Ther 84 413 428
17. Crisby M Nordin-Fredriksson G Shah PK Yano J Zhu J Nilsson J 2001 Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization Circulation 103 926 933
18. Deckers MM Karperien M van der Bent C Yamashita T Papapoulos SE Lowik CW 2000 Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation Endocrinology 141 1667 1674
19. Dietschy JM Turley SD 2001 Cholesterol metabolism in the brain Curr Opin Lipidol 12 105 112
20. Dimmeler S Fleming I Fisslthaler B Hermann C Busse R Zeiher AM 1999 Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation Nature 399 601 605
21. Dimmeler S Aicher A Vasa M et al 2001 HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway J Clin Invest 108 391 397
22. Ducy P Zhang R Geoffroy V Ridall AL Karsenty G 1997 Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation Cell 89 747 754
23. Elovic RP Hipp JA Hayes WC 1995 Maxillary molar extraction causes increased bone loss in the mandible of ovariectomized rats J Bone Miner Res 10 1087 1093
24. Endo A Tsujita Y Kuroda M Tanzawa K 1977 Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase Eur J Biochem 77 31 36
25. Endres M Laufs U Huang Z et al 1998 Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase Proc Natl Acad Sci U S A 95 8880 8885
26. Essig M Nguyen G Prie D Escoubet B Sraer JD Friedlander G 1998 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins Circ Res 83 683 690
27. Eto M Kozai T Cosentino F Joch H Luscher TF 2002 Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways Circulation 105 1756 1759
28. Evans DA Funkenstein HH Albert MS et al 1989 Prevalence of Alzheimer's disease in a community population of older persons JAMA 262 2551 2556
29. Fassbender K Simons M Bergmann C et al 2001 Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo Proc Natl Acad Sci U S A 98 5856 5861
30. Frendo JL Xiao G Fuchs S Franceschi RT Karsenty G Ducy P 1998 Functional hierarchy between two OSE2 elements in the control of osteocalcin gene expression in vivo J Biol Chem 273 30509 30516
31. Frost HM 1997 On our age-related bone loss: insights from a new paradigm J Bone Miner Res 12 1539 1546
32. Fukuyama R Fujita T Azuma Y et al 2004 Statins inhibit osteoblast migration by inhibiting Rac-Akt signaling Biochem Biophys Res Commun 315 636 642
33. Furberg CD 1999 Natural statins and stroke risk Circulation 99 185 188
34. Furchgott RF Zawadzki JV 1980 The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine Nature 288 373 376
35. Garnero P Sornay-Rendu E Claustrat B Delmas PD 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study J Bone Miner Res 15 1526 1536
36. Gerber HP Vu TH Ryan AM Kowalski J Werb Z Ferrara N 1999 VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation Nat Med 5 623 628
37. Gimble JM Robinson CE Wu X Kelly KA 1996 The function of adipocytes in the bone marrow stroma: an update Bone 19 421 428
38. Goldstein JL Brown MS 1990 Regulation of the mevalonate pathway Nature 343 425 430
39. Guijarro C Blanco-Colio LM Ortego M et al 1998 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture Circ Res 83 490 500
40. Gutierrez G Garrett I Rossini G Ecobedo A Horn D Mundy G 2001 Dermal application of lovastatin for 5 days stimulates bone formation in ovariectomized rats by 160% J Bone Miner Res 16 S222
41. Hak AE Pols HA van Hemert AM Hofman A Witteman JC 2000 Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study Arterioscler Thromb Vasc Biol 20 1926 1931
42. Halcox JP Schenke WH Zalos G et al 2002 Prognostic value of coronary vascular endothelial dysfunction Circulation 106 653 658
43. Hamelin BA Turgeon J 1998 Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors Trends Pharmacol Sci 19 26 37
44. Harada H Tagashira S Fujiwara M et al 1999 Cbfa1 isoforms exert functional differences in osteoblast differentiation J Biol Chem 274 6972 6978
45. Heeschen C Hamm CW Laufs U Snapinn S Bohm M White HD 2002 Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes Circulation 105 1446 1452
46. Hernandez-Perera O Perez-Sala D Navarro-Antolin J et al 1998 Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells J Clin Invest 101 2711 2719
47. Hidaka Y Eda T Yonemoto M Kamei T 1992 Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733) Atherosclerosis 95 87 94
48. Huang Z Huang PL Panahian N Dalkara T Fishman MC Moskowitz MA 1994 Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase Science 265 1883 1885
49. Huang PL Huang Z Mashimo H et al 1995 Hypertension in mice lacking the gene for endothelial nitric oxide synthase Nature 377 239 242
50. Huang Z Huang PL Ma J et al 1996 Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro- l -arginine J Cereb Blood Flow Metab 16 981 987
51. Hunziker J Wronski TJ Miller SC 2000 Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone J Dent Res 79 1431 1438
52. Illingworth DR Tobert JA 1994 A review of clinical trials comparing HMG-CoA reductase inhibitors Clin Ther 16 366 385
53. Illingworth DR Tobert JA 2001 HMG-CoA reductase inhibitors Adv Protein Chem 56 77 114
54. Istvan ES Deisenhofer J 2001 Structural mechanism for statin inhibition of HMG-CoA reductase Science 292 1160 1164
55. Izumo N Fujita T Nakamuta H Koida M 2001 Lipophilic statins can be osteogenic by promoting osteoblastic calcification in a Cbfa1- and BMP-2-independent manner Methods Find Exp Clin Pharmacol 23 389 394
56. Jacobs R Ghyselen J Koninckx P van Steenberghe D 1996 Long-term bone mass evaluation of mandible and lumbar spine in a group of women receiving hormone replacement therapy Eur J Oral Sci 104 10 16
57. Jarvinen TL Kannus P Pajamaki I et al 2003 Estrogen deposits extra mineral into bones of female rats in puberty, but simultaneously seems to suppress the responsiveness of female skeleton to mechanical loading Bone 32 642 651
58. Kawane T Takahashi S Saitoh H Okamoto H Kubodera N Horiuchi N 2002 Anabolic effects of recombinant human parathyroid hormone (1-84) and synthetic human parathyroid hormone (1-34) on the mandibles of osteopenic ovariectomized rats with maxillary molar extraction Horm Metab Res 34 293 302
59. Kawane T Terashima S Kurahashi I Yanagawa T Yoshida H Horiuchi N 2004 Atorvastatin enhances bone density in ovariectomized rats given 17beta-estradiol or human parathyroid hormone (1-34) Endocrine 24 121 129
60. Klemetti E Vainio P Lassila V Alhava E 1993 Trabecular bone mineral density of mandible and alveolar height in postmenopausal women Scand J Dent Res 101 166 170
61. Kojro E Gimpl G Lammich S Marz W Fahrenholz F 2001 Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10 Proc Natl Acad Sci U S A 98 5815 5820
62. Kril JJ Halliday GM 2001 Alzheimer's disease: its diagnosis and pathogenesis Int Rev Neurobiol 48 167 217
63. Kureishi Y Luo Z Shiojima I et al 2000 The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals Nat Med 6 1004 1010
64. Kuroda S Mukohyama H Kondo H et al 2003 Bone mineral density of the mandible in ovariectomized rats: analyses using dual energy X-ray absorptiometry and peripheral quantitative computed tomography Oral Dis 9 24 28
65. Kwak B Mulhaupt F Myit S Mach F 2000 Statins as a newly recognized type of immunomodulator Nat Med 6 1399 1402
66. Lacoste L Lam JY Hung J Letchacovski G Solymoss CB Waters D 1995 Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction Circulation 92 3172 3177
67. LaRosa JC He J Vupputuri S 1999 Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials JAMA 282 2340 2346
68. Laufs U Liao JK 1998 Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase J Biol Chem 273 24266 24271
69. Laufs U La Fata V Plutzky J Liao JK 1998 Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1129 1135
70. Lazar MA 2002 Becoming fat Genes Dev 16 1 5
71. Lecka-Czernik B Moerman EJ Grant DF Lehmann JM Manolagas SC Jilka RL 2002 Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation Endocrinology 143 2376 2384
72. Lennernas H Fager G 1997 Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences Clin Pharmacokinet 32 403 425
73. Li X Liu L Tupper JC et al 2002 Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells J Biol Chem 277 15309 15316
74. Li X Cui Q Kao C Wang GJ Balian G 2003 Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures Bone 33 652 659
75. Lips P 1997 Epidemiology and predictors of fractures associated with osteoporosis Am J Med 103 3S 8S
76. Llevadot J Murasawa S Kureishi Y et al 2001 HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells J Clin Invest 108 399 405
77. Mach F Sauty A Iarossi AS et al 1999 Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells J Clin Invest 104 1041 1050
78. Maeda T Matsunuma A Kawane T Horiuchi N 2001 Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells Biochem Biophys Res Commun 280 874 877
79. Maeda T Kawane T Horiuchi N 2003 Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation Endocrinology 144 681 692
80. Maeda T Matsunuma A Kurahashi I Yanagawa T Yoshida H Horiuchi N 2004 Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells J Cell Biochem 92 458 471
81. Margolis RN Canalis E Partridge NC 1996 Invited review of a workshop: anabolic hormones in bone: basic research and therapeutic potential J Clin Endocrinol Metab 81 872 877
82. Maritz FJ Conradie MM Hulley PA Gopal R Hough S 2001 Effect of statins on bone mineral density and bone histomorphometry in rodents Arterioscler Thromb Vasc Biol 21 1636 1641
83. Maron DJ Fazio S Linton MF 2000 Current perspectives on statins Circulation 101 207 213
84. Marz W Koenig W 2003 HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering? J Cardiovasc Risk 10 169 179
85. Meier CR Schlienger RG Kraenzlin ME Schlegel B Jick H 2000 HMG-CoA reductase inhibitors and the risk of fractures JAMA 283 3205 3210
86. Milani RV 2004 Lipid and statin effects on stroke and dementia Am J Geriatr Cardiol 13 25 28
87. Miller SC Hunziker J Mecham M Wronski TJ 1997 Intermittent parathyroid hormone administration stimulates bone formation in the mandibles of aged ovariectomized rats J Dent Res 76 1471 1476
88. Montagnani A Gonnelli S Cepollaro C et al 2003 Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study Bone 32 427 433
89. Mundy GR 2001 Statins and their potential for osteoporosis Bone 29 495 497
90. Mundy G Garrett R Harris S et al 1999 Stimulation of bone formation in vitro and in rodents by statins Science 286 1946 1949
91. Munro E Patel M Chan P et al 1994 Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis Eur J Clin Invest 24 766 772
92. Nakashima Y Raines EW Plump AS Breslow JL Ross R 1998 Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse Arterioscler Thromb Vasc Biol 18 842 851
93. Neer RM Arnaud CD Zanchetta JR et al 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434 1441
94. Nie Q Fan J Haraoka S Shimokama T Watanabe T 1997 Inhibition of mononuclear cell recruitment in aortic intima by treatment with anti-ICAM-1 and anti-LFA-1 monoclonal antibodies in hypercholesterolemic rats: implications of the ICAM-1 and LFA-1 pathway in atherogenesis Lab Invest 77 469 482
95. Nuttall ME Gimble JM 2000 Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis Bone 27 177 184
96. Ohnaka K Shimoda S Nawata H et al 2001 Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts Biochem Biophys Res Commun 287 337 342
97. Ongini E Impagnatiello F Bonazzi A et al 2004 Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties Proc Natl Acad Sci U S A 101 8497 8502
98. Oxlund H Andersen NB Ortoft G Orskov H Andreassen TT 1998 Growth hormone and mild exercise in combination markedly enhance cortical bone formation and strength in old rats Endocrinology 139 1899 1904
99. Oxlund H Dalstra M Andreassen TT 2001 Statin given perorally to adult rats increases cancellous bone mass and compressive strength Calcif Tissue Int 69 299 304
100. Paganini-Hill A 1995 The benefits of estrogen replacement therapy on oral health. The Leisure World cohort Arch Intern Med 155 2325 2329
101. Palmer RM Ferrige AG Moncada S 1987 Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor Nature 327 524 526
102. Parhami F Mody N Gharavi N Ballard AJ Tintut Y Demer LL 2002 Role of the cholesterol biosynthetic pathway in osteoblastic differentiation of marrow stromal cells J Bone Miner Res 17 1997 2003
103. Pasco JA Kotowicz MA Henry MJ Sanders KM Nicholson GC Geelong Osteoporosis Study 2002 Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study Arch Intern Med 162 537 540
104. Pedersen TR Kjekshus J 2000 Statin drugs and the risk of fracture JAMA 284 1921 1922
105. Phillips BW Belmonte N Vernochet C Ailhaud G Dani C 2001 Compactin enhances osteogenesis in murine embryonic stem cells Biochem Biophys Res Commun 284 478 484
106. Radomski MW Palmer RM Moncada S 1990 An l -arginine/nitric oxide pathway present in human platelets regulates aggregation Proc Natl Acad Sci U S A 87 5193 5197
107. Raiteri M Arnaboldi L McGeady P et al 1997 Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation J Pharmacol Exp Ther 281 1144 1153
108. Reid IR Hague W Emberson J et al 2001 Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease Lancet 357 509 512
109. Rejnmark L Buus NH Vestergaard P et al 2004 Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women J Bone Miner Res 19 737 744
110. Rembold C 1996 Could atherosclerosis originate from defective smooth muscle cell death (apoptosis) Perspect Biol Med 39 405 408
111. Ridker PM Rifai N Pfeffer MA et al 1998 Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators Circulation 98 839 844
112. Ridker PM Rifai N Pfeffer MA Sacks F Braunwald E 1999 Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators Circulation 100 230 235
113. Ridker PM Rifai N Clearfield M et al 2001 Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 1959 1965
114. Riggs BL Hartmann LC 2003 Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice N Engl J Med 348 618 629
115. Riggs BL Melton LJ Jr. 1992 The prevention and treatment of osteoporosis N Engl J Med 327 620 627
116. Rodan GA 1998 Mechanisms of action of bisphosphonates Annu Rev Pharmacol Toxicol 38 375 388
117. Romano M Mezzetti A Marulli C et al 2000 Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide J Investig Med 48 183 189
118. Ross R 1993 The pathogenesis of atherosclerosis: a perspective for the 1990s Nature 362 801 809
119. Sakou T 1998 Bone morphogenetic proteins: from basic studies to clinical approaches Bone 22 591 603
120. Schachinger V Britten MB Zeiher AM 2000 Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease Circulation 101 1899 1906
121. Shepherd J Blauw GJ Murphy MB et al 2002 PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 1623 1630
122. Shih PT Brennan ML Vora DK et al 1999 Blocking very late antigen-4 integrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet Circ Res 84 345 351
123. Skoglund B Forslund C Aspenberg P 2002 Simvastatin improves fracture healing in mice J Bone Miner Res 17 2004 2008
124. Song C Guo Z Ma Q et al 2003 Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells Biochem Biophys Res Commun 308 458 462
125. van Staa TP Wegman S de Vries F Leufkens B Cooper C 2001 Use of statins and risk of fractures JAMA 285 1850 1855
126. Staal A Frith JC French MH et al 2003 The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity J Bone Miner Res 18 88 96
127. Stalker TJ Lefer AM Scalia R 2001 A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid Br J Pharmacol 133 406 412
128. -1) in patients with mixed hyperlipidemia Am J Cardiol 86 406 411
129. Stein EA Farnier M Waldstreicher J Mercuri M Simvastatin/Atorvastatin Study Group 2001 Effects of statins on biomarkers of bone metabolism: a randomised trial Nutr Metab Cardiovasc Dis 11 84 87
130. Sugiyama M Kodama T Konishi K Abe K Asami S Oikawa S 2000 Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells Biochem Biophys Res Commun 271 688 692
131. Takenaka M Hirade K Tanabe K et al 2003 Simvastatin stimulates VEGF release via p44/p42 MAP kinase in vascular smooth muscle cells Biochem Biophys Res Commun 301 198 203
132. Tezal M Wactawski-Wende J Grossi SG Ho AW Dunford R Genco RJ 2000 The relationship between bone mineral density and periodontitis in postmenopausal women J Periodontol 71 1492 1498
133. Tintut Y Demer LL 2001 Recent advances in multifactorial regulation of vascular calcification Curr Opin Lipidol 12 555 560
134. Treloar V 2002 Bisphosphonates and osteoporosis N Engl J Med 346 2088 2089
135. Vaughan CJ Gotto AM Jr. Basson CT 2000 The evolving role of statins in the management of atherosclerosis J Am Coll Cardiol 35 1 10
136. Veillard NR Mach F 2002 Statins: the new aspirin Cell Mol Life Sci 59 1771 1786
137. Waldman A Kritharides L 2003 The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia Drugs 63 139 152
138. Wang PS Solomon DH Mogun H Avorn J 2000 HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients JAMA 283 3211 3216
139. Watanabe S Fukumoto S Takeuchi Y Fujita H Nakano T Fujita T 2001 Effects of 1-year treatment with fluvastatin or pravastatin on bone Am J Med 110 584 587
140. Weber C Erl W Weber KS Weber PC 1997 HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia J Am Coll Cardiol 30 1212 1217
141. Weitz-Schmidt G Welzenbach K Brinkmann V et al 2001 Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site Nat Med 7 687 692
142. Wenke K Meiser B Thiery J et al 1997 Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial Circulation 96 1398 1402
143. Wolfrum S Jensen KS Liao JK 2003 Endothelium-dependent effects of statins Arterioscler Thromb Vasc Biol 23 729 736
144. Wolozin B Kellman W Ruosseau P Celesia GG Siegel G 2000 Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors Arch Neurol 57 1439 1443
145. von Wowern N Klausen B Kollerup G 1994 Osteoporosis: a risk factor in periodontal disease J Periodontol 65 1134 1138
146. Yang CM Chien CS Yao CC Hsiao LD Huang YC Wu CB 2004 Mechanical strain induces collagenase-3 (MMP-13) expression in MC3T3-E1 osteoblastic cells J Biol Chem 279 22158 22165
147. Yaturu S 2003 Skeletal effects of statins Endocr Pract 9 315 320
148. Youssef S Stuve O Patarroyo JC et al 2002 The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease Nature 420 78 84
149. Yu ZK Wright JT Hausman GJ 1997 Preadipocyte recruitment in stromal vascular cultures after depletion of committed preadipocytes by immunocytotoxicity Obes Res 5 9 15
150. Zhang FL Casey PJ 1996 Protein prenylation: molecular mechanisms and functional consequences Annu Rev Biochem 65 241 269